New medication targets male baldness
American company Veradermix has developed an experimental oral medication to treat genetic hair loss in men, showing promising results in advanced clinical trials. The study indicated that men who took the drug once daily experienced an average hair growth rate of 28.6 hairs per square centimeter after six months, while those who took it twice daily saw an increase of 36.4 hairs. The medication follows the lead of minoxidil and aims to enhance its effectiveness while reducing the risks associated with oral use. Despite the positive findings, further studies are necessary to confirm its efficacy and safety, with monitoring for side effects such as swelling and unwanted hair growth, though no serious adverse effects have been recorded. The company expects to announce additional study results in 2026 and 2027 and is prepared to introduce the potential product to the market once regulatory evaluations are completed.
Notice: This Is an AI-Generated Summary
Comments (0)